Media Contacts:
Erik Clausen or Kena Hudson
College Hill Life Sciences for Cyntellect, Inc.
(415) 230-5385
Erik.Clausen@collegehill.com or Kena.Hudson@collegehill.com

LEAP™ CELLULAR PURIFICATION AND PROCESSING WORKSTATION FROM CYNTELLECT WINS SELECTSCIENCE SCIENTISTS' CHOICE AWARD FOR BEST DRUG DISCOVERY PRODUCT OF 2009

"LEAP recognized at ELRIG Drug Discovery 2009 Conference for significant contributions to efforts in drug discovery research laboratories"

SAN DIEGO—September 10, 2009—Cyntellect, Inc., a privately-held life sciences company commercializing products to advance life science and stem cell research, biopharmaceutical production, and drug discovery, today received the Scientists' Choice Award for "*Best Drug Discovery Product of 2009*" from SelectScience for its LEAP™ Cellular Purification and Processing Workstation. LEAP was chosen by SelectScience's members and the award was presented at the European Laboratory Robotics Interest Group (ELRIG) Drug Discovery 2009 conference held this week in Liverpool, UK.

"We are delighted to accept this award which is given to recognise technology that significantly contributes towards efforts in drug discovery research laboratories," said Dr. Fred Koller, President and CEO of Cyntellect. "We are very proud to have been chosen as the best from the panel of high quality of products in contention for this honor."

The award-winning LEAP Cellular Purification and Processing Workstation can analyze and purify or process cells with great precision and simplicity in their natural state, allowing cells to maintain their proper physiologic behavior. Cyntellect has collaborated with top academic research institutions and numerous key opinion leaders in the life sciences to validate, refine and enhance the LEAP product.

About Cyntellect

Cyntellect is dedicated to setting new standards in cell analysis, purification, and processing technology. Cyntellect's products support key applications to advance life science research, biopharmaceutical production, stem cell research and drug discovery. The Company's technology employs in situ, microplate-based cytometry

to analyze cells with minimal sample manipulation, and process cells with great precision and efficiency. Cyntellect's expanding cellular analysis and processing portfolio is expected to play an enabling role in the coming age of advanced cell-based diagnostics and therapeutics. For additional information please visit www.cyntellect.com.

###